NeuroMetrix, Inc. Announces Date for 2012 First Quarter Financial Results Conference Call WALTHAM, Mass., Apr 17, 2012 (BUSINESS WIRE) --NeuroMetrix, Inc. (Nasdaq: NURO) today said it plans to issue its 2012 first quarter financial results before the opening of the market on April 24, 2012.

NeuroMetrix to Exhibit at the Midwest Podiatry Conference WALTHAM, Mass. --(BUSINESS WIRE)--Apr. 10, 2012-- NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes reported today that it will exhibit at the

Company is Addressing Diabetes-Related Nerve Disease

Six Month Grace Period to Regain Compliance with Nasdaq Continued Listing Rule

Patient Outreach May Improve Awareness of Diabetic Peripheral Neuropathy

NeuroMetrix Announces Warrant Redemption WALTHAM, Mass. --(BUSINESS WIRE)--Mar. 13, 2012-- NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on the diagnosis and treatment of neurological complications of diabetes, today announced plans to redeem warrants to purchase an aggregate

Will Support a Hands-On Workshop on Evaluation of Diabetic Peripheral Neuropathy

Closes $8.5 Million Public Offering of Common Stock and Warrants

NeuroMetrix, Inc. Announces Date for 2011 Fourth Quarter Financial Results Conference Call WALTHAM, Mass. --(BUSINESS WIRE)--Feb. 10, 2012-- NeuroMetrix, Inc. (Nasdaq: NURO) today said it plans to issue its 2011 fourth quarter financial results before the opening of the market on February 15, 2012

NeuroMetrix Announces Pricing of Securities Offering WALTHAM, Mass. --(BUSINESS WIRE)--Feb. 8, 2012-- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that it has priced a public offering of up to 10,500,000 Units at a price per Unit of $1.00 , for aggregate gross proceeds of up to $10,500,000 ,